Basal Cell Carcinoma Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working

According to the National Cancer Institute, Basal cell carcinomas (BCC) is a type of cancer that begins in the lower part of the epidermis (the outer layer of the skin). BCC is also known as basal cell cancer and is the most common form of skin cancer. It may look like a small white or flesh-colored bump that grows slowly and may bleed. This category of carcinomas is generally found in areas of the body exposed to the sun. BCC is rarely extended to other parts of the body.

Basal cell carcinoma (BCC) most commonly develops on sun-exposed parts of the skin, such as the head and neck. There are many clinical variants of BCC that exist, but the most recognized types are Superficial, Nodular, and Morphea-like BCC. Among all the variants Nodular BCC is the most common.

DelveInsight’s “Basal Cell Carcinoma – Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Basal Cell Carcinoma, historical and forecasted epidemiology as well as the Basal Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

Some of the key facts of the Basal Cell Carcinoma Market Report:

  • BCC is usually a slow-growing tumor for which metastases are rare. It is noteworthy to mention here that, although BCC is rarely fatal, however, it can be highly caustic and damaging to local tissues, when treatment is inadequate or postponed

  • According to an article titled “Skin Cancer: Squamous and Basal Cell Carcinomas” by Bashline, approximately one in five Americans develop skin cancer during their lifetime; 97% of these cancers will be nonmelanoma skin cancers (NMSCs). Basal cell carcinoma (BCC) comprises approximately 80% of NMSCs and most of the remainder are cutaneous squamous cell carcinomas (SCCs)

  • As per the Skin Cancer Foundation, in the US alone, more than four million cases are diagnosed each year with BCCs. BCCs arise from abnormal, uncontrolled growth of basal cells.

Got queries? Click here to know more about the Basal Cell Carcinoma Market Landscape. 

Basal Cell Carcinoma Symptoms: 

  • A translucent, glossy, skin-colored bump with a hint of visibility through the surface. On white skin, the bump can seem pearly white or pink. The bump appears dark or glossy black on brown and black skin

  •  A scaly patch with a raised edge that is flat and scaly. These patches might get fairly huge over time

  •  A change in the skin, such as a growth or an unhealed sore, is a sign of basal cell carcinoma (BCC). 

Basal Cell Carcinoma Market  

The dynamics of the Basal Cell Carcinoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as and others during the forecasted period 2022-2032.

The key companies working for the cure of Basal Cell Carcinoma are - MediWound Ltd, AiViva BioPharma, Inc., SkinJect, Inc., Berg, LLC, Anne Chang, University of Arizona

Learn more by requesting for sample @ Basal Cell Carcinoma Market Landscape 

 Basal Cell Carcinoma Pipeline Therapies: 

  • EscharEx 5% (EX-02 formulation)

  • AIV001

  • API 31510 3% Topical Cream

  • Vismodegib

  • STP705

  • And Many More 

Basal Cell Carcinoma Pipeline Key Companies: 

  • MediWound Ltd

  • AiViva BioPharma, Inc.

  • SkinJect, Inc.

  • Berg, LLC

  • Anne Chang

  • University of Arizona 

Click here to read more about Basal Cell Carcinoma Market Outlook 2032

Related Reports: 

Basal Cell Carcinoma Pipeline 

"Basal Cell Carcinoma Pipeline Insight, 2021" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Basal Cell Carcinoma market. A detailed picture of the Basal Cell Carcinoma pipeline landscape is provided, which includes the disease overview and Basal Cell Carcinoma treatment guidelines.

 Basal Cell Carcinoma Epidemiology 

DelveInsight's 'Basal Cell Carcinoma  Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Basal Cell Carcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Comments

Post a Comment

Popular posts from this blog

Image
B-Cell Chronic Lymphocytic Leukemia Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working CLL (chronic lymphocytic leukemia) is a blood and bone marrow malignancy that affects the spongy tissue inside bones where blood cells are generated.  The word "chronic" originates from the fact that chronic lymphocytic leukemia usually advances more slowly than other types of leukemia. The word "lymphocytic" derives from the cells affected by chronic lymphocytic leukemia, which are a type of white blood cell called lymphocytes that assist your body fight infection. Older People are most prone to get affected by Chronic Lymphocytic Leukemia, and around 95% of the people affected with the CLL have B-cell Chronic Lymphocytic Leukemia .  DelveInsight’s “B-Cell Chronic Lymphocytic Leukemia – Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the B-Cell Chronic Lymphocytic Leukemia, historical and forecasted ...
Read more

Takeda: Spearheading Proteolysis-Targeting Chimera (PROTAC) Development

Image
Bristol Myers Squibb (BMS) has established itself as a trailblazer in the Molecular Glues market , leading innovation in this cutting-edge therapeutic space. Molecular glues are small molecules that facilitate protein-protein interactions, often targeting proteins once considered "undruggable." Their transformative potential is most evident in oncology, where BMS is harnessing this technology to redefine treatment for diseases like Multiple Myeloma. Bristol Myers Squibb — Dominating the Molecular Glue Sector With its stronghold in the molecular glues landscape , BMS has gained a competitive edge by leveraging its robust pipeline and pioneering research. The company’s molecular glue, CC-92480, developed to treat Multiple Myeloma, exemplifies the potential of this technology to degrade specific proteins and halt cancer progression. Its continued advancements in molecular glues demonstrate BMS’s dedication to reshaping the molecular glues competitive landscape . BMS's domina...
Read more

Optimizing Nephrotic Syndrome Management: Anticipated Therapeutic Breakthroughs

Image
Nephrotic syndrome , a condition characterized by the presence of protein in the urine, swelling, low protein levels in the blood, and high cholesterol levels, poses significant challenges for patients and healthcare providers alike. While traditional approaches such as steroids and immunosuppressants have been the mainstay of treatment, emerging therapies offer new hope for individuals battling this debilitating condition. Let's delve into the landscape of nephrotic syndrome treatment, exploring both the current approaches and the promising pipeline therapies on the horizon. Traditional Approaches for Nephrotic Syndrome Treatment: Steroids and Immunosuppressants Historically, steroids and immunosuppressants have been the cornerstone of nephrotic syndrome treatment . These medications help reduce inflammation and suppress the immune system's abnormal response, thereby alleviating symptoms and slowing disease progression. However, their efficacy can vary, and long-term use may b...
Read more